# Day One Reports Fourth Quarter and Full Year 2025 Financial Results and Reaffirms 2026 Outlook and Revenue Guidance
Canonical URL: https://biopharmsignal.com/news/DAWN/day-one-reports-fourth-quarter-and-full-year-2025-financial-results-and-reaffirms-2026-outlook-and-revenue-guidance
Ticker: DAWN
Company: Day One Biopharmaceuticals
Source: Day One Biopharmaceuticals
Published: 2026-02-24 21:00 EST
Original Source URL: https://ir.dayonebio.com
## Summary

OJEMDA™ 2025 momentum reflected by Q4 and full year net product revenues of $52.8 million and $155.4 million, respectively 2026 U.S. net product revenue projected at $225 - $250 million Expanded pipeline with January 2026 acquisition of Mersana Therapeutics; Emi-Le in Phase 1 trial for adenoid

## Article Body
OJEMDA™ 2025 momentum reflected by Q4 and full year net product revenues of $52.8 million and $155.4 million, respectively 2026 U.S. net product revenue projected at $225 - $250 million Expanded pipeline with January 2026 acquisition of Mersana Therapeutics; Emi-Le in Phase 1 trial for adenoid
## Recent Company News
- 2026-03-06 13:30 EST — [Servier and Day One Biopharmaceuticals announce acquisition to expand Servier’s rare oncology portfolio](https://biopharmsignal.com/news/DAWN/servier-and-day-one-biopharmaceuticals-announce-acquisition-to-expand-servier-s-rare-oncology-portfolio) — Source: Day One Biopharmaceuticals
- 2026-02-24 21:00 EST — [Day One Reports Fourth Quarter and Full Year 2025 Financial Results and Reaffirms 2026 Outlook and Revenue Guidance](https://biopharmsignal.com/news/DAWN/day-one-reports-fourth-quarter-and-full-year-2025-financial-results-and-reaffirms-2026-outlook-and-revenue-guidance) — Source: Day One Biopharmaceuticals
- 2026-02-10 13:30 EST — [Day One To Report Fourth Quarter and Full-Year 2025 Financial Results Tuesday, February 24, 2026](https://biopharmsignal.com/news/DAWN/day-one-to-report-fourth-quarter-and-full-year-2025-financial-results-tuesday-february-24-2026) — Source: Day One Biopharmaceuticals
- 2026-01-11 22:00 EST — [Day One Announces Preliminary 2025 OJEMDA™ Net Product Revenue And Provides 2026 Net Product Revenue Guidance](https://biopharmsignal.com/news/DAWN/day-one-announces-preliminary-2025-ojemdatm-net-product-revenue-and-provides-2026-net-product-revenue-guidance) — Source: Day One Biopharmaceuticals
- 2026-01-06 14:02 EST — [Day One Completes Acquisition of Mersana Therapeutics](https://biopharmsignal.com/news/DAWN/day-one-completes-acquisition-of-mersana-therapeutics) — Source: Day One Biopharmaceuticals
## Related News
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)
- 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance  of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)